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Introduction: To characterize etiology, clinical course and outcomes of patients in prolonged refractory status
epilepticus (PRSE) and looking for prognostic factors.
Methods: Retrospective study conducted in patients hospitalized from January 1, 2001 to December 31, 2011 in
19 polyvalent intensive care units in French university and general hospitals. Patients were adults with a generalized
convulsive refractory status epilepticus that lasted more than seven days, despite treatment including an anesthetic
drug and mechanical ventilation. Patients with anoxic encephalopathy were excluded. Follow-up phone call was
used to determine functional outcome using modified Rankin Scale (mRS) with mRS 0–3 defining good and mRS
4–6 poor outcome.
Results: 78 patients (35 female) were included. Median age was 57 years. Causes of status epilepticus were various,
mainly including prior epilepsy (14.1%), CNS infection (12.8%), and stroke (12.8%). No etiology was found in 27
(34.6%) patients. PRSE was considered controlled in only 53 (67.9%) patients after a median duration of 17 (IQR 12–26)
days. The median length of ICU stay was 28 (19–48) days. Forty-one (52.5%) patients died in the ICU, 26 from multiple
organ failure, 8 from care withdrawal, 2 from sudden cardiac arrest, 1 from brain death and 4 from unknown causes.
PRSE was previously resolved in 20 patients who died in the ICU. At one-year follow-up, there were 12 patients with
good outcome and 58 with poor outcome and 8 lost of follow-up. On multivariate analysis, only vasopressor use was
a predictor of poor outcome (OR 6.54; 95%CI 1.09-39.29; p = 0.04).
Conclusion: Poor outcome was observed in about 80% of this population of PRSE. Most patients died from systemic
complications linked to their ICU stay. Some patients can recover satisfactorily over time though we did not identify
any robust factor of good outcome.Introduction
Super-refractory status epilepticus (SE) was recently
defined as a refractory status epilepticus (RSE) that con-
tinues or recurs 24 h or more after the onset of anesthetic
therapy [1,2]. It also includes those cases in which SE
recurs shortly after the reduction or withdrawal of
anesthetic drugs. Others consider the term of late SE
when refractory for more than 48 h [3]. Moreover, the
term of prolonged refractory status epilepticus (PRSE) has
been used for patients with SE that persists or recurs
7 days of more after the onset of continuous general* Correspondence: pe.bollaert@chu-nancy.fr
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unless otherwise stated.anesthesia [4,5]. About 15% of patients admitted to
hospital for SE will become super-refractory [1]. Iden-
tified risk factors are head trauma, stroke and central
nervous system infections [2]. However, super-refractory
SE can occur de novo in people with no history of epilepsy
and in whom no identifiable etiology can be found, so that
it remains a very heterogeneous entity [3]. SE therapy con-
stitutes an emergency for which an early aggressive thera-
peutic approach is required in order to avoid systemic and
neurological complications [3,6,7]. Nevertheless the the-
rapeutic management of prolonged SE remains a terra
incognita with regard to evidence-based medicine [1,8,9].
The prognosis of RSE has long been considered as poor,
including high mortality rates and severe neurological
impairment, which may raise ethical concerns on theis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ever, recent reports suggest that an acceptable recovery
could be observed with time in some patients and that the
PRSE duration should not be by itself a motive for inten-
sive care withdrawal on behalf of futility [4,5,10]. Here we
conducted a multicenter retrospective study to examine
the characteristics, etiological and therapeutic features of
patients with PRSE according to the above-mentioned
definition [4] hospitalized in French ICUs. As in previous
reports, we only considered patients who underwent at
least 7 days of general anesthesia [4,5]. We also attempted
to describe short and long-term prognosis with particular
attention to the evolution of the neurological impairment
from the ICU discharge.Methods
Study participants
We retrospectively evaluated the data on PRSE treated
in the ICU from 1 January 2001 to 31 December 2011.
One hundred and thirty French adult ICUs on a list
published by the French Language Society of Critical
Care Medicine were invited to participate in the study in
September 2012. At each participating ICU, one investi-
gator from the medical staff was responsible for collect-
ing the retrospective data. The diagnosis of prolonged
PRSE was considered in all patients >18 years old suf-
fering from a generalized convulsive SE, which was con-
sidered uncontrolled after general anesthesia (GA) and
mechanical ventilation for at least 7 days. Absence of SE
control was defined as clinical (rhythmic motor move-
ments) or electrical seizures while under treatment or
recurring within 48 h after stopping anesthetic drugs.
Patients with complex partial SE and anoxic encephalop-
athy after cardiac arrest were excluded.Data collection
General data included the simplified acute physiological
score (SAPS II), the length of ICU stay and common co-
morbidities often associated with SE. We also recorded
the antiepileptic drugs administered from the beginning
to the end of the SRSE, the duration of SRSE, the type
of neurological monitoring, and the existence of an elec-
trical interruption in the seizure or burst-suppression
during the first 7 days. Morbidity and mortality at ICU
discharge were also recorded. The degree of disability
was estimated with the modified Rankin Scale (mRS) be-
fore hospitalization, at ICU discharge, at last news from
the patient, and, if available, at one year after ICU dis-
charge [11]. The functional outcome was dichotomized
into good (mRS 0 to 3) and poor (mRS 4 to 6) [12]. To
obtain this information, local investigators had to con-
tact the attending physician, the patient or the patient’s
family.Statistical methods
Descriptive results for continuous variables were ex-
pressed as mean and standard deviation or as median
and interquartile range, depending on the normality of
their distribution. Variables were tested for their associ-
ation with prognosis by using Pearson’s chi-squared test
for categorical data and the Mann-Whitney U-test for
numerical data. A multiple stepwise logistic regression
model was established with any covariate with univariate
significance of a P-value less than 0.10 eligible for inclu-
sion in the model. The model was then further calibrated
through Hosmer-Lemeshow testing.
Ethical considerations
The study was approved by the Ethics Committee of the
French Language Society of Critical Care Medicine. Ac-
cording to French law on non-interventional and retro-
spective studies, patients received information about the
study and non-opposition to their participation in the
study was sought.
Results
Among the 130 ICUs invited to participate, 15 reported
that no patients fulfilled the inclusion criteria, 19 admitted
at least one patient who fulfilled the inclusion criteria in
the study period and the remaining ICU provided no in-
formation. A total of 78 patients were included. Their
baseline characteristics are displayed on Table 1. The eti-
ology of the SE was known or highly suspected in 51
(65.4%) patients and led to a specific treatment when
available.
Seventy (89.7%) patients received intravenous benzodi-
azepines, two received sodium valproate and four under-
went GA as their first-line treatment in the attempt to
control the seizures. Sixty-five patients (83.4%) had a
second-line treatment with anti-epileptic drugs (AED)
including fosphenytoin (n = 35), phenobarbital (n = 23),
levetiracetam (n = 2), sodium valproate (n = 5) and
oxcarbazepine (n = 1) and nine underwent GA. Twenty-
seven patients received a third-line AED, including
phenobarbital (n = 10), fosphenytoin (n = 10), sodium
valproate (n = 5) and levetiracetam (n = 2). During the
first week of GA, 65 patients were treated with a median
of 2 (1 to 3) other AED, usually through the enteral
route. The agents used to induce GA as a first-, second-
or third-line treatment were thiopental (n = 58), propo-
fol (n = 17), ketamine (n = 1), halogenated gas (n = 1),
combined or switched with continuous midazolam infu-
sion (n = 55) in the first 7 days of SE. After 7 days of un-
successful treatment, GA was continued using various
anesthetic drugs, including thiopental (80%), midazolam
(47%), propofol (25%) and in some anecdotal cases, keto-
genic diet (n = 7), immunoglobulin infusion (n = 1),
vagal stimulation (n = 1), and electroconvulsivotherapy
Table 1 Baseline characteristics of patients
Patients characteristics Value in 78 patients
Age, years 57 (36 to 70)
Female 35 (44.8)
History of epilepsy 26 (33.3)
History of alcoholism 27 (34.6)
History of stroke 10 (12.8)
Existing central nervous system pathology 2 (2.5)





Central nervous system infection 10 (12.8)
Metabolic encephalopathy 5 (6.4)
Neurodegenerative disease 4 (5.1)
Drug abuse 4 (5.1)
Post neurosurgery 4 (5.1)
Inflammatory encephalitis 3 (3.8)
Unknown 27 (34.6)







Simplified acute physiology score II 52.8 ± 14.6
Data are number (%), mean ± SD, or median (IQR). aData were missing in
two patients.
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encephalogram (EEG) in all but one patient who under-
went continuous EEG monitoring. EEG burst suppression
was observed in 48 patients (61%) within the first 7 days.
All patients were mechanically ventilated from the
time they received general anesthesia. Administration
of vasopressors and renal replacement was required
in 60 and 14 patients, respectively. Nosocomial infec-
tions were observed in 60 patients, 27 of them with
at least one episode of ventilator-associated pneumonia. A
thrombo-embolic event occurred in five patients. PRSE
was considered controlled in 53 (67.9%) patients after a
median length of 17 (12 to 26) days of general anesthesia.
The median length of ICU stay was 28 (19 to 48) days.
Withholding or withdrawing care was decided in 16
and 8 patients, respectively, after a median stay of 20 (14
to 25) days. Motivations of therapeutic limitation inclu-
ded persistent RSE without improvement or identifiable
etiology, stroke with major brain lesions, multiple organfailure, pre-existent chronic alcoholism with neurological
and/or hepatic complications, and cerebral tumor without
available treatment. Half of the 16 patients who under-
went withholding of care survived, only one of them with
a good functional outcome at one year (mRS = 2) and all
patients who underwent withdrawal of care died. Forty-
one (52.5%) patients died in the ICU. Among them, 26
died from multiple organ failure secondary to sepsis, 8
from care withdrawal, 2 from sudden cardiac arrest, 1
from brain death subsequent to severe intracranial hyper-
tension and 4 from unknown causes. PRSE had previously
been resolved in 20 patients who died in the ICU.
Surviving patients (47.5%; n = 37) were followed after
ICU discharge. Five patients died within one year after
ICU discharge. Eight patients were lost to follow up.
Twenty-four of the remaining patients had at least one
year of follow up. Between ICU discharge and one-year
follow up, 13 patients (54.1% of the survivors) had sei-
zures, six of them having a previously known history of
epilepsy. However, no recurrence of SE was observed.
ICU-acquired paresis was present in 14 patients (58.2% of
the survivors).
As shown in Figure 1, there was a marked decline in
functional status between admission and ICU discharge
with a median increase in mRS of 4 (3 to 5). At one-year
follow up, 12 (17.1%) patients had a good outcome with
a median mRS decrease of −1 (−2.5 to −1) as compared
with ICU discharge mRS.
Univariate analysis (Table 2) showed that male gender,
younger age, EEG burst-suppression observed within 7
days, introduction of an etiological treatment and no need
for vasopressors were associated with a better one-year
outcome. On multivariate analysis, only the use of vaso-
pressors remained significantly predictive of outcome
(odds ratio = 6.54; 95% confidence interval 1.09, 39.29;
P = 0.04). Underlying coexisting illnesses and etiology of
PRSE were not related to outcome, except for stroke
where all patients (n = 10) had a poor outcome. Drugs
used for GA had no statistically significant effect on
outcome. The duration of SE did not differ according to
outcome. Figure 2 shows that a good outcome is pos-
sible after more than 30 days of SE. However, all pa-
tients whose SE was unresolved after 60 days (n = 3)
and those who stayed more than 90 days in the ICU had
a poor outcome (n = 8: extremes 90 to 300 days).
Discussion
In this multicenter study, we identified 78 patients with
generalized convulsive PRSE from various causes except
anoxia over 10 years. All patients underwent at least 7
days of general anesthesia after failure of first-line, and
for almost all, second-line anti-epileptic therapies. Overall
prognosis was poor, with more than 50% of patients not
surviving their ICU stay. Of note, a significant number of
Figure 1 Distributions of scores according to the modified Rankin scale (mRS) on admission, ICU discharge and one-year followup. Data are lacking
for two patients on ICU admission; eight patients were lost to follow up at one year.
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status improved thereafter, so that at one-year follow up,
nearly half of survivors followed up had good functional
outcome. Seeking to identify predictive variables of long-
term outcome, we found that systemic complications
related to the management of PRSE are probably more
relevant than direct SE-related brain damage.
Overall characteristics of the present population did
not differ from published series of refractory SE with
regard to age and sex ratio in this population excluding
children and young adults <18 years old. However, his-
tory of epilepsy was found in only one-third of patients,
a lower proportion than in cohorts of unselected patients
with SE where 47 to 67% rates have been reported [13-15].
Although many different causes of super-refractory SE were
observed, no etiology was found in one third of patients.
This finding contrasts with other series of super-refractory
SE where absence of diagnosis was <20% [4,5,16]. InTable 2 Univariate analysis according to one-year outcome
Good outcome (mRS ≤3) n
Male gender 9 (75)
Age, years 42 (31 to 62)]
Simplified acute physiology score II 46.9 ± 12.8
Admission mRS 0.5 (0 to 1)
Known cause of PRSE 7 (58.3)
Thiopental for general anesthesia 11 (91.7)
EEG burst suppression within 7 days 9 (75)
Status epilpticus duration, days 15 (11 to 37)
Length of ICU stay, days 35 (20 to 49)
Etiological treatment 8 (66.7)
Vasopressors 4 (33.3)
Nosocomial infections 10 (83.3)
Seizures after ICU discharge 3 (25)
ICU-acquired polyneuropathy 6 (50)
Data are number (%), mean ± SD or median (IQR). aPatients with complete available
refractory status epilepticus; EEG, electroencephalogram.addition, the relatively low proportion of patients with
encephalitis in the present study also differs from other
super-refractory SE cohorts where up to 35 to 45% of
encephalitis were observed [5,16]. It may be hypothesized
that some inflammatory encephalitis where cerebro-spinal
fluid and imaging alterations are sometimes absent or very
subtle could have been either underdiagnosed or consid-
ered only as a hypothetical etiology.
Use of AED drugs was heterogeneous among patients,
a finding that was not unexpected in a multicenter retro-
spective study over ten years. Although American rec-
ommendations for the management of status epilepticus
were available in 1993 [17] and French recommenda-
tions in 1995 then updated in 2009 [7], more precise
guidelines about RSE were only recently implemented
[18,19]. That could explain the low use of propofol as
compared with barbiturates observed in the present
study, whereas based on higher mortality rates observed= 12 Poor outcome (mRS >3) n = 51a P-value
30 (58.8) 0.01
58 (45 to 71) 0.07
53.9 ± 15.4 0.65




17 (11 to 22) 0.95






data; bonly in ICU survivors. mRS, modified Rankin scale; PRSE, prolonged
Figure 2 Modified Rankin scale of one-year survivors according to status epilepticus duration.
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retrospective studies [7,20], the latter anesthetic drug
could be preferred [18]. However, use of thiopental had
no prognostic value in the present study, as in a recent
single-center cohort with RSE reported by Hocker et al.
[12], so that this question remains controversial.
About 50% of patients did not survive the ICU stay.
ICU mortality was a little higher than in previous series
of patients with PRSE using the same inclusion criteria,
with 43 and 34% of ICU mortality respectively [4,5], but
was worse than in RSE where in-hospital mortality rates
ranged from 15 to 30% [3,12,21,22]. Of interest, median
SE duration was <4 days in two series reporting 16 and
17% RSE mortality respectively [21,22], mean SE dur-
ation was 11 days in a series of patients with RSE with
31% mortality [12], and finally, median SE duration
ranged from 17 to 19 days in the present study and in
the two other studies of PRSE [4,5], which suggests a
close correlation between the duration of RSE and ICU
mortality. Of note, only one patient died directly from a
neurological cause (brain herniation and cerebral death).
A majority of patients died from multi-organ failure, in
relation to nosocomial infections and sepsis. Although
this rate appears higher than in other series of patients
with PRSE, infectious complications were also frequently
observed while their causative role in precipitating death
was unclear [4,12]. Others died from life-supporting
treatment withdrawal, often the main cause of death in
other series [4,12], which could mask or prevent other
causes of death, including sepsis. Almost half of the
non-survivors no longer had SE at the time of death.
Taken together, causes of death and resolution of SE in
most non-survivors suggest that iatrogenic events may
play an important role in outcome. That the rate of
complications could have been reduced by a larger use
of propofol instead of thiopental is possible, but specula-
tive [1,3,16].
Most patients discharged alive had severe functional
impairment. However, functional improvement was ob-
served in some patients so that about 50% of the survivorsfollowed up for one year had a good outcome. Surpris-
ingly, seizures were not frequent and no recurrence of SE
was observed during follow up as previously observed [5],
which suggests that the high resistance of SE to treatment
does not predict further drug-resistant epilepsy once
controlled.
We sought to identify variables associated with long-
term poor outcome. Age was modestly associated with
outcome but not in multivariate analysis; a previous
meta-analysis of refractory SE found the same associ-
ation in 193 refractory SE patients [23], but it was not
retrieved in more recent cohorts of refractory SE [12,14]
or PRSE [5]. Surprisingly, both SE duration and length
of ICU stay did not significantly differ between popu-
lations with poor or good outcome. However, we also
observed that no patient with an SE duration >60 days
and/or an ICU stay >90 days had a good outcome. The
latter finding is consistent with previous published co-
horts of patients with PRSE [5,12]. However, the absence
of a statistical link between SE duration and outcome in
PRSE does not imply that SE duration is not relevant for
prognosis: as exposed above, overall mortality is corre-
lated with median duration of SE, patients with extreme
SE duration display a very poor prognosis and SE dur-
ation is the determinant of duration of GA. Finally, as
also observed in the other cohorts with PRSE [4,5,12],
some patients may achieve a good outcome with very
prolonged SE duration which could explain the absence
of statistical significance of SE duration on long-term
outcome within our study and others [4,12]. EEG burst-
suppression within 7 days of treatment was weakly asso-
ciated with a good outcome in univariate but not multi-
variate analysis: this could be either an indicator of the
degree of drug resistance or a marker of a better thera-
peutic strategy but we are unable to conclude further on
that point. The availability of a causative treatment was
associated with a good outcome, which is supported by
medical common sense, cohort studies [24] and clinical
reports where only control of a pathogenic event resolved
very prolonged PRSE [25].
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ated with poor outcome in multivariate analysis. The
high odds ratio was matched with a large confidence
interval of limited statistical significance. In a retrospect-
ive cohort of 144 episodes of SE, Kowalski et al. showed
that the need for mechanical ventilation, vasopressors or
third-line anesthetic drugs was associated with poor out-
come [26]. These covariates were linked together, so that
only the use of third-line anesthetic drugs remained sig-
nificant on multivariate analysis. In the present study,
both anesthetic drugs and mechanical ventilation were
applied to every patient, which explains their absence of
effect on outcome. Vasopressors were always prescribed
to correct an arterial hypotension and not to increase
cerebral perfusion pressure. While hypotension is com-
mon when using thiopental, propofol or even midazolam
[23], it could alternatively be subsequent to or potenti-
ated by sepsis, cardio-pulmonary interactions during
mechanical ventilation and various other causes. While
direct deleterious effects of vasopressors cannot be ruled
out [27], the cause of hypotension, including anesthetic
drugs, should be considered. Indeed, whatever the cause
and mechanisms of vasopressor adverse effects, we have
to acknowledge that the strongest prognosis factor we
found is more linked to adverse effects of ICU care than
SE by itself. In this way, the strong relationship between
SE duration and poor prognosis could at least be par-
tially explained by systemic complications of ICU care,
especially prolonged general anesthetic drug administra-
tion [9,28,29].
About 30% of patients were given a decision to with-
hold or withdraw life-sustaining therapy. A decision to
withdraw life-sustaining therapy was the second cause of
death in our series and the first cause in two recent stud-
ies in patients with RSE [12] and PRSE [4]. In the present
study, most decisions were related to previous severe
comorbidities, severe brain damage (stroke, Creutzfeldt-
Jakob disease, brain tumor) or multiple organ failure.
All patients in whom life-support care was withdrawn
(mechanical ventilation, vasopressors) died shortly after
withdrawal of care, whereas patients in whom only
withholding therapy (no cardiac arrest resuscitation, no
therapeutic escalation) was decided survived. Although
survival of ICU patients who were given a decision to
limit treatment appears surprising, their long-term out-
come was very poor (mRS = 5 or death) except for one
patient with a mRS of 2. This patient died 6 months
later from hepatic cirrhosis (one of the motivations for
withholding care).
We are aware that this study has several limitations. It
was a retrospective study of a heterogeneous cohort with
regard to drug therapy. A selection bias cannot be ruled
out with regard to the absence of contribution from the
majority of invited ICUs. As in most multicenter studies,management varied by center and the retrospective na-
ture of the study did not allow us to record all pertinent
data. The etiology of PRSE was diverse, which did not
allow us to identify some causes of PRSE associated with
good outcomes. In addition, both the absence of moni-
toring of SE using continuous EEG and suboptimal
achievement of EEG burst-supression or suppression-
pattern goals are no longer in agreement with the most
recent recommendations [18,19] We assessed outcome
using the mRS, which is a recognized scale of autonomy,
but it does not inform about quality of life. Finally, the
multivariate analysis would have been more robust with
a larger population. However, to our knowledge, this is
currently the largest available multicenter series of pa-
tients with prolonged PRSE.
Conclusions
This multicenter study confirms that prolonged PRSE
leads to high morbidity and mortality rates with about
80% of patients having a poor outcome at one-year fol-
low up. Most patients died from systemic complications
linked to their ICU stay, or treatment withdrawal for
ethical purposes, while in the meantime, SE had resolved
in half of them. However, half of long-term survivors
recovered satisfactorily over time, though we did not
identify any robust factor of good outcome. Even though
randomized controlled studies may be extremely difficult
to conduct in such a rare disease, the present findings
urge for the need at least for large observational pro-
spective studies.
Key messages
 Prolonged refractory status epilepticus leads to high
mortality
 Most patients die from systemic complications more
related to their management in the intensive care
unit than to brain damage
 Half of long-term survivors have a good outcome
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